In vitro equivalence evaluation of betahistine generic medicinal products as a tool potentially determining the efficacy of pharmacotherapy

O.I. Butranova

Peoples’ Friendship University of Russia, Medical Institute, Department of General and Clinical Pharmacology. Moscow, Russia

G.V. Ramenskaya

Sechenov First Moscow State Medical University, Moscow, Russia

G.N. Gildeeva

Sechenov First Moscow State Medical University, Moscow, Russia

I.E. Shohin

Center of Pharmaceutical Analytic Ltd., Moscow, Russia

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(11): 43–48

In vitro equivalence evaluation of betahistine generic medicinal products as a tool potentially determining the efficacy of pharmacotherapy

Authors:

O.I. Butranova, G.V. Ramenskaya, G.N. Gildeeva, I.E. Shohin

More about the authors

DOI: 10.17116/jnevro201811811143

Read: 5880 times

Open to cite this article

Butranova OI, Ramenskaya GV, Gildeeva GN, Shohin IE. In vitro equivalence evaluation of betahistine generic medicinal products as a tool potentially determining the efficacy of pharmacotherapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(11):43‑48. (In Russ., In Engl.).
https://doi.org/10.17116/jnevro201811811143

Close metadata

Objective. To compare release parameters of various betahistine drugs in vitro using a comparative dissolution kinetics test. Material and methods. Objects of research are solid dosage forms (tablets) containing betahistine in a dose of 24 mg permitted for medical use in the Russian Federation. A method of comparative dissolution kinetics test was carried out as follows. The study was performed on a paddle stirrer at a speed of 50 rpm in three different pH dissolution media (pH 1.2, 4.5, 6.8), simulating the main sections of the digestive tract in which the active ingredient was decomposed, released and absorbed. This was performed in a quality controlled environment using a citrate buffer solution with pH 6.8. The time points for sampling the medium were 10 min, 15 min, 20 min and 30 min. Results. The results of betahistine release were significant (RSD<10%) for all time points, except the first time point (RSD<20%). Regardless of pH, there was a complete release (≥85% over 15 minutes, <10%) of betahistine from betaserc, 24 mg, tablets (manufactured by Mylan Laboratories SAS). The dissolution profiles of betahistine in other investigational drugs did not show complete drug release (parameter <85% in 15 minutes, <10%) in different pH media. Therefore, dissolution profiles of the studied drugs were not comparable to the reference profile. Conclusion. Starting from 10 minutes, the reference drug of betahistine (betaserc, 24 mg) has a consistently higher release at different pH levels (representing the various stages of gastric digestion), vs. other studied generic analogues showing significantly lower levels of betahistine release. None of the studied drugs were found to be equivalent in vitro.

Keywords:

reference drug of betahistine

generic analogues of betahistine

in vitro equivalence of generics

Authors:

O.I. Butranova

Peoples’ Friendship University of Russia, Medical Institute, Department of General and Clinical Pharmacology. Moscow, Russia

G.V. Ramenskaya

Sechenov First Moscow State Medical University, Moscow, Russia

G.N. Gildeeva

Sechenov First Moscow State Medical University, Moscow, Russia

I.E. Shohin

Center of Pharmaceutical Analytic Ltd., Moscow, Russia

List of references:

Lacour M, Sterkers O. Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action. CNS Drugs. 2001;15:853-870. https://doi.org/10.2165/00023210-200115110-00004
Soto E, Vega R. Neuropharmacology of vestibular system disorders. Curr Neuropharmacol. 2010;8:26-40. https://doi.org/10.2174/157015910790909511
Redon C, Lopez C, Bernard-Demanze L, Dumitrescu M, Magnan J, Lacour M, Borel L. Betahistine treatment improves the recovery of static symptoms in patients with unilateral vestibular loss. J Clin Pharmacol. 2011;51:538-548. https://doi.org/10.1177/0091270010369241
Murdin L, Hussain K, Schilder AG. Betahistine for symptoms of vertigo. Cochrane Database Syst Rev. 2016;21(6):CD010696. https://doi.org/10.1002/14651858.CD010696
Timmerman H. Pharmacotherapy of vertigo: any news to be expected? Acta Otolaryngol (Stockh.). 1994;513(suppl):28-32. https://doi.org/10.3109/00016489409127323
Dunne S, Shannon B, Dunne C, Cullen W. A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study. BMC Pharmacol Toxicol. 2013;14:1. https://doi.org/10.1186/2050-6511-14-1
Privitera MD. Generic Antiepileptic Drugs: Current Controversies and Future Directions. Epilepsy Curr. 2008;8(5):113-117. https://doi.org/10.1111/j.1535-7511.2008.00261.x
Mayer T, May TW, Altenmuller DM, Sandmann M, Wolf P. Clinical Problems with Generic Antiepileptic Drugs: Comparison of Sustained-Release Formulations of Carbamazepine. Clin Drug Investig. 1999;18(1):17-26. https://doi.org/10.2165/00044011-199918010-00003
Crawford P, Feely M, Guberman A, Kramer G. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure. 2006;15(3):165-176. https://doi.org/10.1016/j.seizure.2005.12.010
Ihler F, Bertlich M, Sharaf K, Strieth S, Strupp M, Canis M. Betahistine exerts a dose-dependent effect on cochlear stria vascularis blood flow in guinea pigs in vivo. PLoS ONE. 2012;7:e39086. https://doi.org/10.1371/journal.pone.0039086
Bertlich M, Ihler F, Sharaf K, Weiss BG, Strupp M, Canis M. Betahistine metabolites, aminoethylpyridine, and hydroxyethylpyridine increase cochlear blood flow in guinea pigs in vivo. Int J Audiol. 2014;53:753-759. https://doi.org/10.3109/14992027.2014.917208
Bertlich M, Ihler F, Freytag S, Weiss BG, Strupp M, Canis M. Histaminergic H3-heteroreceptors as a potential mediator of betahistine-induced increase in cochlear blood flow. Audiol Neuro Otol. 2015;20:283-293. https://doi.org/10.1159/000368293
Bertlich M, Ihler F, Weiss BG, Freytag S, Strupp M, Jakob M, Canis M. Role of capillary pericytes and precapillary arterioles in the vascular mechanism of betahistine in a guinea pig inner ear model. Life Sci. 2017;187:17-21. https://doi.org/10.1016/j.lfs.2017.08.015
Tighilet B, Mourre C, Trottier S, Lacour M. Histaminergic ligands improve vestibular compensation in the cat: behavioural, neurochemical and molecular correlates. Eur J Pharmacol. 2007;446(b):63-73. https://doi.org/10.1016/j.ejphar.2007.04.052
Anand O, Yu LX, Conner DP, Davit BM. Dissolution testing for generic drugs: an FDA perspective. AAPS J. 2011;13(3):328-335. https://doi.org/10.1208/s12248-011-9272-y
Guide to the examination of medicines. Volume I. M.: Grif and K.; 2013. (In Russ.)
Guidelines for the examination of medicinal products. Volume III. M.: POLIGRAF-PLUS; 2014. (In Russ.)
Adrion C, Fischer CS, Wagner J, Gürkov R, Mansmann U, Strupp M. Efficacy and safety of betahistine treatment in patients with Meniere’s disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial. BMJ. 2016;352:h6816. https://doi.org/10.1136/bmj.h6816
Strupp M, Hupert D, Frenzel C, Wagner J, Hahn A, Jahn K, et al. Long-term prophylactic treatment of attacks of vertigo in Menière’s disease—comparison of a high with a low dosage of betahistine in an open trial. Acta Otolaryngol. 2008;128:520-524. https://doi.org/10.1080/00016480701724912
Tighilet B, Léonard J, Watabe I, Bernard-Demanze L, Lacour M. Betahistine Treatment in a Cat Model of Vestibular Pathology: Pharmacokinetic and Pharmacodynamic Approaches. Front Neurol. 2018;9:431. https://doi.org/10.3389/fneur.2018.00431